Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)‘s stock had its “buy” rating restated by stock analysts at SunTrust Banks, Inc. in a report released on Wednesday. They presently have a $80.00 price target on the biopharmaceutical company’s stock. SunTrust Banks, Inc.’s price target suggests a potential upside of 13.88% from the company’s previous close.

A number of other research firms have also weighed in on AGIO. Janney Montgomery Scott lowered shares of Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, June 26th. Cann restated a “buy” rating and set a $75.00 target price on shares of Agios Pharmaceuticals in a research report on Sunday, June 11th. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Royal Bank Of Canada started coverage on Agios Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 price target for the company. Finally, Oppenheimer Holdings, Inc. set a $75.00 price target on Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, June 11th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $75.20.

Shares of Agios Pharmaceuticals (AGIO) traded up 1.39% during midday trading on Wednesday, reaching $70.25. The company had a trading volume of 1,017,271 shares. Agios Pharmaceuticals has a one year low of $39.24 and a one year high of $71.40. The company has a 50 day moving average price of $62.68 and a 200-day moving average price of $55.80. The firm’s market capitalization is $3.40 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.21). The business had revenue of $11.30 million during the quarter, compared to the consensus estimate of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business’s revenue for the quarter was up 62.1% on a year-over-year basis. During the same period last year, the firm earned ($1.47) EPS. On average, analysts anticipate that Agios Pharmaceuticals will post ($7.07) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/04/agios-pharmaceuticals-inc-agio-rating-reiterated-by-suntrust-banks-inc.html.

In related news, insider Scott Biller sold 2,146 shares of the company’s stock in a transaction that occurred on Friday, July 7th. The shares were sold at an average price of $55.00, for a total value of $118,030.00. Following the transaction, the insider now directly owns 8,410 shares in the company, valued at $462,550. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Lewis Clayton Jr. Cantley sold 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $56.14, for a total transaction of $196,490.00. Following the completion of the transaction, the director now owns 86,697 shares in the company, valued at $4,867,169.58. The disclosure for this sale can be found here. Insiders sold a total of 131,938 shares of company stock worth $8,205,572 over the last 90 days. Corporate insiders own 10.55% of the company’s stock.

A number of institutional investors have recently made changes to their positions in AGIO. Lord Abbett & CO. LLC grew its stake in Agios Pharmaceuticals by 81.5% in the 2nd quarter. Lord Abbett & CO. LLC now owns 266,910 shares of the biopharmaceutical company’s stock worth $13,733,000 after buying an additional 119,836 shares in the last quarter. Public Employees Retirement System of Ohio increased its holdings in shares of Agios Pharmaceuticals by 52.8% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 18,353 shares of the biopharmaceutical company’s stock worth $944,000 after buying an additional 6,338 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Agios Pharmaceuticals by 20.7% in the 2nd quarter. California State Teachers Retirement System now owns 74,157 shares of the biopharmaceutical company’s stock worth $3,816,000 after buying an additional 12,716 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Agios Pharmaceuticals by 1,041.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 3,123 shares in the last quarter. Finally, State Street Corp raised its position in shares of Agios Pharmaceuticals by 8.1% during the 2nd quarter. State Street Corp now owns 1,302,966 shares of the biopharmaceutical company’s stock valued at $67,036,000 after buying an additional 97,220 shares in the last quarter. Institutional investors and hedge funds own 94.40% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.